Glivec

Banner image with text: 'Stay informed with the latest IP news' and the following words listed: Insights, Interviews, Webinars.

India’s Supreme Court rejects patent plea by Novartis for the cancer drug Glivec

By Jeanette Jakobsson | Posted on April 18, 2013

For years, India did not offer any patent protection for chemical compounds, but was obliged to do this after joining the World Trade Organization. In 2005, the patent protection act therefore was amended to also include such compounds, but only if they proved significant clinical efficacy enhancements over already patented compounds, Section 3(d) of the Indian...

Tags: Bayer, Glivec, Novartis, Roche

Recent contributors

Laura Stravinskaite

Laura Stravinskaite

Senior Associate, Attorney at Law

Ai-Leen Lim

Ai-Leen Lim

Partner, Attorney at Law, Group Vice President

Ashley Zhao

Ashley Zhao

Partner, Attorney at Law, Business Area Manager

Troels Peter Rørdam

Troels Peter Rørdam

Senior Counsel, European Patent Attorney

Mikkel Roed Trier

Mikkel Roed Trier

Partner, European Patent Attorney, UPC Representative, Business Area Manager